NASDAQ : ACET
Adicet Bio, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.42 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 36.81M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 35.52M |
| Enterprise Value | -69.81M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 9.36M |
| Shares Outstanding | 10.76M |
| Shares Change (YoY) | +65.16% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 3.16% |
| Owned by Institutions (%) | 38.81% |
| Float | 7.18M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.31 |
| P/TBV Ratio | 0.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.71 |
| Quick Ratio | 6.59 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,280.35 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -78.08% |
| Return on Assets (ROA) | -41.66% |
| Return on Invested Capital (ROIC) | -46.02% |
| Return on Capital Employed (ROCE) | -79.67% |
| Weighted Average Cost of Capital (WACC) | 9.83% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$970,333 |
| Employee Count | 102 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 143,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.63 |
| 52-Week Price Change | -71.52% |
| 50-Day Moving Average | 7.15 |
| 200-Day Moving Average | 7.69 |
| Relative Strength Index (RSI) | 18.52 |
| Average Volume (20 Days) | 207,142 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 521,883 |
| Short Previous Month | 485,466 |
| Short % of Shares Out | 4.85% |
| Short % of Float | 7.27% |
| Short Ratio (days to cover) | 1.52 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -103.71M |
| Pretax Income | -98.83M |
| Net Income | -98.97M |
| EBITDA | -98.12M |
| EBIT | -103.71M |
| Earnings Per Share (EPS) | -$10.52 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 118.19M |
| Total Debt | 12.85M |
| Net Cash | 105.34M |
| Net Cash Per Share | $9.79 |
| Equity (Book Value) | 120.14M |
| Book Value Per Share | 11.16 |
| Working Capital | 102.76M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -84.53M |
| Capital Expenditures | -438,000 |
| Depreciation & Amortization | 5.59M |
| Net Borrowing | -150,000 |
| Free Cash Flow | -84.97M |
| FCF Per Share | -$7.89 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -65.16% |
| Shareholder Yield | -65.16% |
| Earnings Yield | -318.77% |
| FCF Yield | -239.19% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $34.83 |
| Price Target Difference | 955.46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:16 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |